Page 32 - 2018_09-Mondo

S. Bringhen et al.
Safety of proteasome inhibitors for treat-
ment of multiple myeloma. Expert Opin
Drug Saf. 2017;16(2):167-183.
37. Stewart AK, Rajkumar SV, Dimopoulos MA,
et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
38. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753-1761.
39. Hájek R, Russell SD, Lyon A, et al. A sub- study of the phase 3 ENDEAVOR study: serial echocardiographic assessment of patients with relapsed multiple myeloma (RMM) receiving carfilzomib plus dexam- ethasone or bortezomib plus dexametha- sone. Haematologica. 2016;101(S1):263.
40. Hájek R, Masszi T, Petrucci MT, et al. A ran- domized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refracto- ry multiple myeloma (FOCUS). Leukemia. 2017;31(1):107-114.
41. Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127(26):3360-3368.
42. Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359-2367.
43. Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the european myeloma net- work. Leukemia. 2018 May 2. [Epub ahead of print]
44. Lee JH, Huang SY, Liu JH, et al. Outcomes for Asian patients with relapsed multiple myeloma treated with carfilzomib and dex- amethasone Vs bortezomib and dexametha- sone: a subgroup analysis of the phase 3 ENDEAVOR Study (NCT01568866). Haematologica. 2016;101(S1):549-550.
45. Dimopoulos MA, Siegel D, White DJ, et al. Superior efficacy of carfilzomib and dexam- ethasone (Kd56) vs bortezomib and dexam- ethasone (Vd) in multiple myeloma (MM) patients with moderate or serious renal fail- ure: a sobgroup analysis of the phase 3 ENDEAVOR study. Blood. 2017;130(Suppl 1):1845.
46. Sugumar D, Keller J, Vij R. Targeted treat-
ments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med. 2015;20;8:23-33.
47. Facon T, Lee JH, Moreau P, et al. CLARION: Phase 3 study of carfilzomib, melphalan, prednisone vs bortezomib, melphalan, pred- nisone in newly diagnosed multiple myelo- ma. Clin Lymphoma Myeloma Leuk. 2017;17(Suppl):e26-e27.
48. Data available at https://www.amgen.com/ media/news-releases/2016/09/amgen- announces-topline-results-from-phase-3- kyprolis-carfilzomib-clarion-study-in- newly-diagnosed-multiple-myeloma- patients/
49. Boccia RV, Bessudo A, Agajanian R, et al. A multicenter, open-label, phase 1b study of carfilzomib, cyclophosphamide, and dex- amethasone in newly diagnosed multiple myeloma patients (CHAMPION-2). Clin Lymphoma Myeloma Leuk. 2017;17(7):433- 437.
50. Bringhen S, Petrucci MT, Giuliani N, et al. An integrated analysis of cardio-vascular adverse events of carfilzomib, cyclophos- phamide and dexamethasone in elderly newly diagnosed myeloma patients enrolled in 3 phase I/II trials. Blood. 2016;128(22): 3336.
51. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combi- nation with lenalidomide and low-dose dex- amethasone as a frontline treatment for mul- tiple myeloma. Blood. 2012;120(9):1801- 1809.
52. Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99:e162-e164.
53. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dex- amethasone in patients with newly diag- nosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
54. Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979-985.
55. Gay F, Rota Scalabrini D , Belotti A, et al. Carfilzomib-lenalidomide-dexamethasone vs carfilzomib-cyclophosphamide-dexam- ethasone induction: planned interim analy- sis of the randomized FORTE trial in newly diagnosed multiple myeloma. J Clin Oncol.
2017;35(Suppl 15):8003.
56. Atrash S, Tullos A, Panozzo S, et al. Cardiac
complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5:e272.
57. Lenihan DJ, Potluri R, Bhandari H, Ranjan S and Chen C. Evaluation of cardiovascular comorbidities among patients with multiple myeloma in the United States. Blood. 2016;128(4):479-487.
58. Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6(1):e384.
59. Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1):e272- e272.
60. Pawlyn C, Davies F, Cairns D, et al. Quadruplet vs sequential triplet induction Therapy for myeloma patients: results of the MYELOMA XI study. Haematologica. 2017; 102(S2):142.
61. Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophos- phamide, carfilzomib, thalidomide and dex- amethasone) for newly diagnosed myelo- ma. Br J Haematol. 2015;169(2):219-227.
62. Wester R, van der Holt B, Asselbergs E, et al. Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction/consolidation in newly diag- nosed, transplant eligible patients with mul- tiple myeloma, the carthadex trial. Blood. 2016;128(22):1141.
63 Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide- dexamethasone with lenalidomide exten- sion in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746-754.
64. Chari A, Aggarwal S, Mezzi K, et al. Cardiac events in real-world multiple myeloma patients treated with carfilzomib: a retro- spective claims database analysis. Blood. 2016;128(22):3319.
65. Rosenthal AC, Luthi J, Belohlavek M, et al. The cardiovascular impact of carfilzomib in multiple myeloma. Blood. 2014;124(21): 4748.
66. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449-454.
1432
haematologica | 2018; 103(9)